Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Steven E. Schutzer is active.

Publication


Featured researches published by Steven E. Schutzer.


PLOS ONE | 2010

Establishing the Proteome of Normal Human Cerebrospinal Fluid

Steven E. Schutzer; Tao Liu; Benjamin H. Natelson; Thomas E. Angel; Athena A. Schepmoes; Samuel O. Purvine; Kim K. Hixson; Mary S. Lipton; David G. Camp; Patricia K. Coyle; Richard D. Smith; Jonas Bergquist

Background Knowledge of the entire protein content, the proteome, of normal human cerebrospinal fluid (CSF) would enable insights into neurologic and psychiatric disorders. Until now technologic hurdles and access to true normal samples hindered attaining this goal. Methods and Principal Findings We applied immunoaffinity separation and high sensitivity and resolution liquid chromatography-mass spectrometry to examine CSF from healthy normal individuals. 2630 proteins in CSF from normal subjects were identified, of which 56% were CSF-specific, not found in the much larger set of 3654 proteins we have identified in plasma. We also examined CSF from groups of subjects previously examined by others as surrogates for normals where neurologic symptoms warranted a lumbar puncture but where clinical laboratory were reported as normal. We found statistically significant differences between their CSF proteins and our non-neurological normals. We also examined CSF from 10 volunteer subjects who had lumbar punctures at least 4 weeks apart and found that there was little variability in CSF proteins in an individual as compared to subject to subject. Conclusions Our results represent the most comprehensive characterization of true normal CSF to date. This normal CSF proteome establishes a comparative standard and basis for investigations into a variety of diseases with neurological and psychiatric features.


The Lancet | 1990

Sequestration of antibody to Borrelia burgdorferi in immune complexes in seronegative Lyme disease

Steven E. Schutzer; P.K. Coyle; A.L. Belman; M.G. Golightly; J. Drulle

To find out whether apparent seronegativity in patients strongly suspected of having Lyme disease can be due to sequestration of antibodies in immune complexes, such complexes were isolated and tested for antibody to Borrelia burgdorferi. In a blinded analysis the antibody was detected in all 10 seronegative Lyme disease patients with erythema chronicum migrans (ECM), in none of 19 patients with other diseases, and in 4 of 12 seronegative patients who probably had Lyme disease but had no ECM. These findings were confirmed by western blot, which also showed that immune complex dissociation liberated mainly antibody reactive to the 41 kD antigen and sometimes antibody to an approximate 30 kD antigen. Complexed B burgdorferi antibody was also found in 21 of 22 (95%) of seropositive patients with active disease, 3 additional seronegative but cell mediated immune reactive patients, and 3 other seronegative patients who eventually became seropositive. Apparent B burgdorferi seronegativity in serum immune complexes may thus be due to sequestration of antibody in immune complexes.


Journal of Bacteriology | 2011

Whole Genome Sequences of Thirteen Isolates of Borrelia burgdorferi

Steven E. Schutzer; Claire M. Fraser-Liggett; Sherwood Casjens; Wei-Gang Qiu; John J. Dunn; Emmanuel F. Mongodin; Benjamin J. Luft

Borrelia burgdorferi is a causative agent of Lyme disease in North America and Eurasia. The first complete genome sequence of B. burgdorferi strain 31, available for more than a decade, has assisted research on the pathogenesis of Lyme disease. Because a single genome sequence is not sufficient to understand the relationship between genotypic and geographic variation and disease phenotype, we determined the whole-genome sequences of 13 additional B. burgdorferi isolates that span the range of natural variation. These sequences should allow improved understanding of pathogenesis and provide a foundation for novel detection, diagnosis, and prevention strategies.


PLOS ONE | 2012

Genome Stability of Lyme Disease Spirochetes: Comparative Genomics of Borrelia burgdorferi Plasmids

Sherwood R. Casjens; Emmanuel F. Mongodin; Wei-Gang Qiu; Benjamin J. Luft; Steven E. Schutzer; Eddie B. Gilcrease; Wai Mun Huang; Marija Vujadinovic; John Aron; Levy C. Vargas; Sam Freeman; Diana Radune; Janice Weidman; George Dimitrov; Hoda Khouri; Julia Sosa; Rebecca A. Halpin; John J. Dunn; Claire M. Fraser

Lyme disease is the most common tick-borne human illness in North America. In order to understand the molecular pathogenesis, natural diversity, population structure and epizootic spread of the North American Lyme agent, Borrelia burgdorferi sensu stricto, a much better understanding of the natural diversity of its genome will be required. Towards this end we present a comparative analysis of the nucleotide sequences of the numerous plasmids of B. burgdorferi isolates B31, N40, JD1 and 297. These strains were chosen because they include the three most commonly studied laboratory strains, and because they represent different major genetic lineages and so are informative regarding the genetic diversity and evolution of this organism. A unique feature of Borrelia genomes is that they carry a large number of linear and circular plasmids, and this work shows that strains N40, JD1, 297 and B31 carry related but non-identical sets of 16, 20, 19 and 21 plasmids, respectively, that comprise 33–40% of their genomes. We deduce that there are at least 28 plasmid compatibility types among the four strains. The B. burgdorferi ∼900 Kbp linear chromosomes are evolutionarily exceptionally stable, except for a short ≤20 Kbp plasmid-like section at the right end. A few of the plasmids, including the linear lp54 and circular cp26, are also very stable. We show here that the other plasmids, especially the linear ones, are considerably more variable. Nearly all of the linear plasmids have undergone one or more substantial inter-plasmid rearrangements since their last common ancestor. In spite of these rearrangements and differences in plasmid contents, the overall gene complement of the different isolates has remained relatively constant.


PLOS ONE | 2011

Distinct Cerebrospinal Fluid Proteomes Differentiate Post-Treatment Lyme Disease from Chronic Fatigue Syndrome

Steven E. Schutzer; Thomas E. Angel; Tao Liu; Athena A. Schepmoes; Therese R. Clauss; Joshua N. Adkins; David G. Camp; Bart Holland; Jonas Bergquist; Patricia K. Coyle; Richard D. Smith; Brian Fallon; Benjamin H. Natelson

Background Neurologic Post Treatment Lyme disease (nPTLS) and Chronic Fatigue (CFS) are syndromes of unknown etiology. They share features of fatigue and cognitive dysfunction, making it difficult to differentiate them. Unresolved is whether nPTLS is a subset of CFS. Methods and Principal Findings Pooled cerebrospinal fluid (CSF) samples from nPTLS patients, CFS patients, and healthy volunteers were comprehensively analyzed using high-resolution mass spectrometry (MS), coupled with immunoaffinity depletion methods to reduce protein-masking by abundant proteins. Individual patient and healthy control CSF samples were analyzed directly employing a MS-based label-free quantitative proteomics approach. We found that both groups, and individuals within the groups, could be distinguished from each other and normals based on their specific CSF proteins (p<0.01). CFS (n = 43) had 2,783 non-redundant proteins, nPTLS (n = 25) contained 2,768 proteins, and healthy normals had 2,630 proteins. Preliminary pathway analysis demonstrated that the data could be useful for hypothesis generation on the pathogenetic mechanisms underlying these two related syndromes. Conclusions nPTLS and CFS have distinguishing CSF protein complements. Each condition has a number of CSF proteins that can be useful in providing candidates for future validation studies and insights on the respective mechanisms of pathogenesis. Distinguishing nPTLS and CFS permits more focused study of each condition, and can lead to novel diagnostics and therapeutic interventions.


PLOS ONE | 2010

Genotypic Variation and Mixtures of Lyme Borrelia in Ixodes Ticks from North America and Europe

Chris D. Crowder; Heather Matthews; Steven E. Schutzer; Megan A. Rounds; Benjamin J. Luft; Oliver Nolte; Scott R. Campbell; Curtis Phillipson; Feng Li; Ranga Sampath; David J. Ecker; Mark W. Eshoo

Background Lyme disease, caused by various species of Borrelia, is transmitted by Ixodes ticks in North America and Europe. Studies have shown the genotype of Borrelia burgdorferi sensu stricto (s.s.) or the species of B. burgdorferi sensu lato (s.l.) affects the ability of the bacteria to cause local or disseminated infection in humans. Methodology/Principal Findings We used a multilocus PCR electrospray mass spectrometry assay to determine the species and genotype Borrelia from ticks collected in New York, Connecticut, Indiana, Southern Germany, and California and characterized isolates from parts of the United States and Europe. These analyses identified 53 distinct genotypes of B. burgdorferi sensu stricto with higher resolution than ospC typing. Genotypes of other members of the B. burgdorferi sensu lato complex were also identified and genotyped including B. afzelii, B. garinii, B. lusitaniae, B. spielmanii, and B. valaisiana. While each site in North America had genotypes unique to that location, we found genotypes shared between individual regions and two genotypes found across the United States. Significant B. burgdorferi s.s. genotypic diversity was observed between North America and Europe: only 6.6% of US genotypes (3 of 45) were found in Europe and 27% of the European genotypes (3 of 11) were observed in the US. Interestingly, 39% of adult Ixodes scapularis ticks from North America were infected with more than one genotype of B. burgdorferi s.s. and 22.2% of Ixodes ricinus ticks from Germany were infected with more than one genotype of B. burgdorferi s.l. Conclusions/Significance The presence of multiple Borrelia genotypes in ticks increases the probability that a person will be infected with more than one genotype of B. burgdorferi, potentially increasing the risks of disseminated Lyme disease. Our study indicates that the genotypic diversity of Borrelia in ticks in both North America and Europe is higher then previously reported and can have potential clinical consequences.


Applied and Environmental Microbiology | 2005

Toward a System of Microbial Forensics: from Sample Collection to Interpretation of Evidence

Bruce Budowle; Steven E. Schutzer; Michael Ascher; Ronald M. Atlas; James P. Burans; Ranajit Chakraborty; John J. Dunn; Claire M. Fraser; David R. Franz; Terrance J. Leighton; Stephen A. Morse; Randall S. Murch; Jacques Ravel; D. L. Rock; Thomas R. Slezak; Stephan P. Velsko; Anne Walsh; Ronald A. Walters

The threat of terrorist or criminal use of pathogenic organisms and their toxins remains a great concern in the United States. The anthrax letter attack of 2001 ([12][1]) raised the awareness of our vulnerability. It also demonstrated the need to perform microbial forensic analyses for attribution


Journal of Clinical Investigation | 1994

EARLY AND SPECIFIC ANTIBODY RESPONSE TO OSPA IN LYME DISEASE

Steven E. Schutzer; P K Coyle; J J Dunn; Benjamin J. Luft; M Brunner

Borrelia burgdorferi (Bb), the cause of Lyme disease, has appeared not to evoke a detectable specific antibody response in humans until long after infection. This delayed response has been a biologic puzzle and has hampered early diagnosis. Antibody to the abundant organism-specific outer surface proteins, such as the 31-kD OspA, has rarely been detected less than 6 mo after infection. Antibody to a less organism-specific 41-kD flagellin protein, sharing common determinants with other bacteria and thus limiting its diagnostic potential, may appear after 4 to 6 wks. To investigate our hypothesis that specific antibody to OspA may actually be formed early but remain at low levels or bound in immune complexes, we analyzed serum samples from patients with concurrent erythema migrans (EM). This is the earliest sign of Lyme disease and occurs in 60-70% of patients, generally 4-14 d after infection. We used less conventional but more sensitive methods: biotin-avidin Western blots and immune complex dissociation techniques. Antibody specificity was confirmed with recombinant OspA. Specific complexed antibody to whole Bb and recombinant OspA was detected in 10 of 11 of the EM patients compared to 0 of 20 endemic area controls. IgM was the predominant isotype to OspA in these EM patients. Free IgM to OspA was found in half the EM cases. IgM to OspA was also detected in 10 of 10 European patients with EM who also had reactive T cells to recombinant OspA. In conclusion a specific antibody response to OspA occurs early in Lyme disease. This is likely to have diagnostic implications.


Genome Biology and Evolution | 2010

Continuing Evolution of Burkholderia mallei Through Genome Reduction and Large-Scale Rearrangements

Liliana Losada; Catherine M. Ronning; David DeShazer; Donald E. Woods; Natalie D. Fedorova; H. Stanley Kim; Svetlana A. Shabalina; Talima Pearson; Lauren M. Brinkac; Patrick Tan; Tannistha Nandi; Jonathan Crabtree; Jonathan H. Badger; Stephen M. Beckstrom-Sternberg; Muhammad Saqib; Steven E. Schutzer; Paul Keim; William C. Nierman

Burkholderia mallei (Bm), the causative agent of the predominately equine disease glanders, is a genetically uniform species that is very closely related to the much more diverse species Burkholderia pseudomallei (Bp), an opportunistic human pathogen and the primary cause of melioidosis. To gain insight into the relative lack of genetic diversity within Bm, we performed whole-genome comparative analysis of seven Bm strains and contrasted these with eight Bp strains. The Bm core genome (shared by all seven strains) is smaller in size than that of Bp, but the inverse is true for the variable gene sets that are distributed across strains. Interestingly, the biological roles of the Bm variable gene sets are much more homogeneous than those of Bp. The Bm variable genes are found mostly in contiguous regions flanked by insertion sequence (IS) elements, which appear to mediate excision and subsequent elimination of groups of genes that are under reduced selection in the mammalian host. The analysis suggests that the Bm genome continues to evolve through random IS-mediated recombination events, and differences in gene content may contribute to differences in virulence observed among Bm strains. The results are consistent with the view that Bm recently evolved from a single strain of Bp upon introduction into an animal host followed by expansion of IS elements, prophage elimination, and genome rearrangements and reduction mediated by homologous recombination across IS elements.


Emerging Infectious Diseases | 2014

Prevalence of Borrelia miyamotoi in Ixodes Ticks in Europe and the United States

Chris D. Crowder; Heather E. Carolan; Megan A. Rounds; Václav Hönig; Benedikt Mothes; Heike Haag; Oliver Nolte; Ben J. Luft; Libor Grubhoffer; David J. Ecker; Steven E. Schutzer; Mark W. Eshoo

Infection rates of Ixodes ticks with Borrelia miyamotoi in Europe and the United States vary greatly based upon location.

Collaboration


Dive into the Steven E. Schutzer's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Wei-Gang Qiu

City University of New York

View shared research outputs
Top Co-Authors

Avatar

Bruce Budowle

University of North Texas Health Science Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

John J. Dunn

Brookhaven National Laboratory

View shared research outputs
Top Co-Authors

Avatar

Stephen A. Morse

Centers for Disease Control and Prevention

View shared research outputs
Researchain Logo
Decentralizing Knowledge